keyword
MENU ▼
Read by QxMD icon Read
search

Anti-VEGF

keyword
https://www.readbyqxmd.com/read/29784048/a-meta-analysis-of-the-effect-of-a-dexamethasone-intravitreal-implant-versus-intravitreal-anti-vascular-endothelial-growth-factor-treatment-for-diabetic-macular-edema
#1
Ye He, Xin-Jun Ren, Bo-Jie Hu, Wai-Ching Lam, Xiao-Rong Li
BACKGROUND: This meta-analysis evaluated the effectiveness and safety of dexamethasone (DEX) implant and intravitreal anti-vascular endothelial growth factor (VEGF) treatment for diabetic macular edema (DME). METHODS: The PubMed, Embase, clinicaltrials.gov website and Cochrane Library databases were comprehensively searched for studies comparing DEX implant with anti-VEGF in patients with DME. Best-corrected visual acuity (BCVA), central subfield thickness (CST) and adverse events were extracted from the final eligible studies...
May 21, 2018: BMC Ophthalmology
https://www.readbyqxmd.com/read/29781343/issues-and-promises-of-bevacizumab-in-prostate-cancer-treatment
#2
Vittore Cereda, Vincenzo Formica, Mario Roselli
There is general agreement that increased angiogenesis is an important factor in determining prostate cancer development and prognosis. Vascular Endothelial Growth Factor (VEGF) is thought to play a primary role in the molecular events that lead to prostate cancer progression, from androgen-dependency to castration-resistance until dissemination to the skeleton. Bevacizumab is a recombinant anti-VEGF monoclonal antibody that has exhibited clinical activity in different cancer types. Areas covered: In this review we summarize the data of clinical trials, investigating the effects of bevacizumab in prostate cancer patients...
May 21, 2018: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/29781319/assessing-the-role-of-ranibizumab-in-improving-the-outcome-of-glaucoma-filtering-surgery-and-neovascular-glaucoma
#3
Andreas Katsanos, Kostantina Gorgoli, Dimitrios G Mikropoulos, Esther Arranz-Marquez, Georgios P Athanasopoulos, Miguel A Teus, Anastasios G P Konstas
Ranibizumab was the first anti-vascular endothelial growth factor (VEGF) agent approved for the treatment of neovascular age-related macular degeneration. The use of ranibizumab and other anti-VEGF medications in recent years has revolutionized the treatment of several sight-threatening retinal disorders. Emerging evidence has demonstrated that anti-VEGF treatment can offer advantages in the management of other ocular conditions where VEGFs play a key role: ocular scarring following glaucoma filtering surgery and neovascular glaucoma (NVG)...
May 19, 2018: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/29780944/central-retinal-artery-occlusion-secondary-to-barlow-s-disease
#4
Carl S Wilkins, Katherine McCabe, Avnish Deobhakta, James Chelnis
Purpose: To report a rare case of isolated, unilateral CRAO in a young patient with mitral valve prolapse secondary to Barlow's disease. Observations: A 29-year-old woman with history of premature ventricular contractions and cardiac ablation presented to the emergency room after sudden onset painless visual loss in her left eye (OS). Her vision was 20/20 in her right eye and hand motion in the left. Fundus exam demonstrated a central retinal artery occlusion (CRAO) OS...
June 2018: American Journal of Ophthalmology Case Reports
https://www.readbyqxmd.com/read/29779188/vitreomacular-interface-abnormalities-in-patients-with-diabetic-macular-oedema-and-their-implications-on-the-response-to-anti-vegf-therapy
#5
Michael Mikhail, Stephen Stewart, Felicia Seow, Ruth Hogg, Noemi Lois
PURPOSE: To determine whether the presence of vitreomacular interface abnormalities (VMIA) in patients with diabetic macular oedema (DMO) modifies the response to ranibizumab. METHODS: Medical records and spectral-domain optical coherence tomography (SD-OCT) scans of consecutive patients with centre-involving DMO initiating therapy with ranibizumab between December 2013 and March 2014 at the Belfast Health and Social Care Trust were reviewed. Patients were identified through an electronic database...
May 19, 2018: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/29776963/combined-vegf-and-pd-l1-blockade-displays-synergistic-treatment-effects-in-an-autochthonous-mouse-model-of-small-cell-lung-cancer
#6
Lydia Meder, Philipp Schuldt, Martin Thelen, Anna Schmitt, Felix Dietlein, Sebastian Klein, Sven Borchmann, Kerstin Wennhold, Ignacija Vlasic, Sebastian Oberbeck, Richard Riedel, Alexandra Florin, Kristina Golfmann, Hans Anton Schlößer, Margarete Odenthal, Reinhard Büttner, Juergen Wolf, Michael Hallek, Marco Herling, Michael von Bergwelt-Baildon, Hans Christian Reinhardt, Roland T Ullrich
Small cell lung cancer (SCLC) represents the most aggressive pulmonary neoplasm and is often diagnosed at late stage with limited survival, despite combined chemotherapies. We show in an autochthonous mouse model of SCLC that combined anti-VEGF/anti-PD-L1 targeted therapy synergistically improves treatment outcome compared to anti-PD-L1 and anti-VEGF monotherapy. Mice treated with anti-PD-L1 alone relapsed after 3 weeks and were associated with a tumor-associated PD-1/TIM-3 double positive exhausted T cell phenotype...
May 18, 2018: Cancer Research
https://www.readbyqxmd.com/read/29774103/bevacizumab-exacerbates-sinusoidal-obstruction-syndrome-sos-in-the-animal-model-and-increases-mmp-9-production
#7
Azin Jafari, Hanno Matthaei, Sven Wehner, Tolga Tonguc, Jörg C Kalff, Steffen Manekeller
Background: Thanks to modern multimodal treatment the ouctome of patients with colorectal cancer has experienced significant improvements. As a downside, agent specific side effects have been observed such as sinusoidal obstruction syndrome (SOS) after oxaliplatin chemotherapy (OX). Bevazicumab targeting VEGF is nowadays comprehensively used in combination protocols with OX but its impact on hepatotoxicity is thus far elusive and focus of the present study. Results: After MCT administration 67% of animals developed SOS...
April 24, 2018: Oncotarget
https://www.readbyqxmd.com/read/29772041/endophthalmitis-associated-with-intravitreal-injections-of-anti-vegf-agents-at-a-tertiary-referral-center-in-house-and-referred-cases
#8
Nicolas A Yannuzzi, Ninel Z Gregori, Philip J Rosenfeld, Nidhi Relhan, Nimesh A Patel, Nancy Si, Darlene Miller, Sander R Dubovy, William E Smiddy, Stephen G Schwartz, Harry W Flynn
BACKGROUND AND OBJECTIVE: To report the incidence rates, causative organisms, and visual acuity (VA) outcomes in patients with endophthalmitis associated with intravitreal injection of anti-vascular endothelial growth factor inhibitors. PATIENTS AND METHODS: Retrospective case series between 2005 and 2017. RESULTS: The study included 39 eyes of 39 patients, including 27 (69%) referred and 12 (31%) institutional patients. The use of topical antibiotics after an injection was gradually phased out at the authors' institution, where the preinjection rate of all clinically suspected endophthalmitis was 0...
May 1, 2018: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/29771880/-anti-vegf-therapy-for-diabetic-macular-edema-from-theory-to-clinical-practice
#9
A Zh Fursova, N V Chubar, M S Tarasov, I F Niculich, M A Vasilyeva, O G Gusarevich
PURPOSE: To evaluate clinical effectiveness of aflibercept therapy for patients with diabetic macular edema (DME) - both naïve to the drug and unresponsive to previous anti-VEGF treatment. MATERIAL AND METHODS: The study included 127 patients (127 eyes) divided into two groups. The first group consisted of 100 primary DME patients (100 eyes) with mean age of 68.48±2.56 years and average disease duration of 12.50±7.85 years. The second group comprised 27 patients (27 eyes) with resistant macular edema who had received three or more 0...
2018: Vestnik Oftalmologii
https://www.readbyqxmd.com/read/29769445/vegf-vegfr2-blockade-does-not-cause-retinal-atrophy-in-amd-relevant-models
#10
Da Long, Yogita Kanan, Jikui Shen, Sean F Hackett, Yuanyuan Liu, Zibran Hafiz, Mahmood Khan, Lili Lu, Peter A Campochiaro
Intraocular injections of VEGF-neutralizing proteins provide tremendous benefits in patients with choroidal neovascularization (NV) due to age-related macular degeneration (AMD), but during treatment some patients develop retinal atrophy. Suggesting that VEGF is a survival factor for retinal neurons, a clinical trial group attributed retinal atrophy to VEGF suppression and cautioned against frequent anti-VEGF injections. This recommendation may contribute to poor outcomes in clinical practice from insufficient treatment...
May 17, 2018: JCI Insight
https://www.readbyqxmd.com/read/29768269/long-term-results-of-combination-treatment-with-single-dose-ranibizumab-plus-photodynamic-therapy-for-retinal-angiomatous-proliferation
#11
Panagiotis Malamos, Ioannis Tservakis, Menelaos Kanakis, Chrysoula Koutsiouki, Evita Kiskira, Georgios Mylonas, John Lakoumentas, Ilias Georgalas
PURPOSE: To present functional and anatomic outcomes of combination therapy with ranibizumab and photodynamic therapy (PDT) in a series of retinal angiomatous proliferation (RAP) cases. METHODS: A total of 17 eyes of 17 patients with RAP were included. Thirteen eyes were treatment naïve and 4 were already on ranibizumab monotherapy. Combined treatment with single-dose ranibizumab and PDT was performed on all treatment-naïve cases. Follow-up was performed every month for 6-38 months, using optical coherence tomography and indocyanine green angiography when necessary...
May 16, 2018: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/29768266/subfoveal-choroidal-thickness-in-eyes-with-neovascular-age-related-macular-degeneration-treated-with-anti-vascular-endothelial-growth-factor-agents
#12
Tereza Cristina Moreira Kanadani, Carlos Eduardo Veloso, Márcio B Nehemy
PURPOSE: We aimed to assess the subfoveal choroidal thickness (SFChT) and the effect of treatment with anti-vascular endothelial growth factor (anti-VEGF) agents on the SFChT in age-related macular degeneration (AMD) subtypes. METHODS: We enrolled 128 eyes of 107 patients with neovascular AMD (60 women; 47 men; mean age, 73.6 ± 8.9 years), and prospectively evaluated the best-corrected visual acuity (BCVA) and SFChT at baseline and at 3, 6, and 12 months after treatment with anti-VEGF agents...
May 16, 2018: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/29765959/outcome-of-5-year-treatment-of-neovascular-age-related-macular-degeneration-with-intravitreal-anti-vegf-using-treat-and-extend-regimen
#13
Polona Jaki Mekjavic, Polona Zaletel Benda
Objective: The aim of this study is twofold. First , to evaluate the long-term outcome of anti-vascular endothelial growth factor (anti-VEGF) treatment in a clinical setting using the "treat-and-extend regimen" (TER) in patients with neovascular age-related macular degeneration (nAMD). Second , to determine the proportion of patients treated with anti-VEGF with good visual acuity (VA), i.e., vision sufficient to maintain a high level of independence. Design: We conducted a single center retrospective review of patients with treatment-naive nAMD who were treated with anti-VEGF...
2018: Frontiers in Medicine
https://www.readbyqxmd.com/read/29764162/the-evolving-role-of-immune-oncology-in-colorectal-cancer
#14
Shaheenah Dawood
Metastatic colorectal cancer still remains an essentially non curable disease. However, with advances in chemotherapeutic and personalizing therapeutic approaches with the incorporation of targeted therapy such as anti-EGFR and anti-VEGF agents survival associated with metastatic colorectal cancer has certainly improved over the last two decades. Patients who are not amenable to surgery median survival remain approximately 2 to 3 years. In an attempt to improve prognostic outcome over the last decade research has focused on therapeutic options geared towards harnessing the immune system with success observed with the use of immune checkpoint inhibitors in the realm of a number of solid tumors including lung and renal cancer...
April 2018: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29755821/is-there-a-relationship-between-use-of-anti-vascular-endothelial-growth-factor-agents-and-atrophic-changes-in-age-related-macular-degeneration-patients
#15
REVIEW
Süleyman Kaynak, Mahmut Kaya, Derya Kaya
Choroidal neovascularization due to age-related macular degeneration (AMD) is currently treated successfully with anti-vascular endothelial growth factor (VEGF) intravitreal agents. Emerging evidence suggests that anti-VEGF treatment may potentially increase development of geographic atrophy. However, there is not yet direct proof of a causal relationship between geographic atrophy and use of anti-VEGF agents in neovaskuler AMD. The aim of this review is to discuss the evidence concerning the association between anti-VEGF therapy and progression of geographic atrophy...
April 2018: Turkish Journal of Ophthalmology
https://www.readbyqxmd.com/read/29755695/hypertension-in-malignancy-an-underappreciated-problem
#16
REVIEW
Jolanta Małyszko, Maciej Małyszko, Leszek Kozlowski, Klaudia Kozlowska, Jacek Małyszko
Hypertension is one of the most common comorbidities in cancer patients with malignancy, in particular, in the elderly. On the other hand, hypertension is a long-term consequence of antineoplastic treatment, including both chemotherapy and targeted agents. Several chemotherapeutics and targeted drugs may be responsible for development or worsening of the hypertension. The most common side effect of anti-VEGF (vascular endothelial growth factor) treatment is hypertension. However, pathogenesis of hypertension in patients receiving this therapy appears to be associated with multiple pathways and is not yet fully understood...
April 17, 2018: Oncotarget
https://www.readbyqxmd.com/read/29755678/functional-invadopodia-formed-in-glioblastoma-stem-cells-are-important-regulators-of-tumor-angiogenesis
#17
Christos Petropoulos, Pierre-Olivier Guichet, Konstantin Masliantsev, Michel Wager, Lucie Karayan-Tapon
Glioblastoma (GBM) represents the most common and lethal brain tumor. High vascularization, necrosis and invasiveness are hallmarks of GBM aggressiveness with recent data suggesting the important role of glioblastoma stem cells (GSCs) in these processes. It is now well established that cancer cells employ specialized structures termed invadosomes to potentiate invasion. However, the role of these structures in GBM dissemination remains poorly investigated. In this study, we showed that GBM-isolated GSCs form invadopodia-like protrusions endowed with degradative action...
April 17, 2018: Oncotarget
https://www.readbyqxmd.com/read/29748595/crispr-lbcpf1-prevents-choroidal-neovascularization-in-a-mouse-model-of-age-related-macular-degeneration
#18
Taeyoung Koo, Sung Wook Park, Dong Hyun Jo, Daesik Kim, Jin Hyoung Kim, Hee-Yeon Cho, Jeungeun Kim, Jeong Hun Kim, Jin-Soo Kim
LbCpf1, derived from Lachnospiraceae bacterium ND2006, is a CRISPR RNA-guided endonuclease and holds promise for therapeutic applications. Here we show that LbCpf1 can be used for therapeutic gene editing in a mouse model of age-related macular degeneration (AMD). The intravitreal delivery of LbCpf1, targeted to two angiogenesis-associated genes encoding vascular endothelial growth factor A (Vegfa) and hypoxia inducing factor 1a (Hif1a), using adeno-associated virus, led to efficient gene disruption with no apparent off-target effects in the retina and retinal pigment epithelium (RPE) cells...
May 10, 2018: Nature Communications
https://www.readbyqxmd.com/read/29746405/long-term-physical-stability-sterility-and-anti-vegf-bioactivity-of-repackaged-bevacizumab-in-2-ml-glass-vials
#19
Jan S Peterson, Kenneth Rockwell, Ingrid U Scott, Michael S Ip, Paul C VanVeldhuisen, Barbara A Blodi
PURPOSE: Repackaged bevacizumab in single-dose, prefilled syringes for intravitreal injection is available, but with shelf life limited from 60 days to 90 days. For the Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2), 2-mL sterile glass vials were used rather than prefilled syringes to provide a longer shelf life for study supplies. METHODS: Repackaged bevacizumab in glass vials was tested at release and, for 1 lot, after 1, 3, 6, and 12 months for physical stability, including concentration, purity and appearance, and for sterility and endotoxins...
May 9, 2018: Retina
https://www.readbyqxmd.com/read/29744040/recent-advances-in-understanding-and-managing-retinal-vein-occlusions
#20
REVIEW
Daniel D Esmaili, David S Boyer
Retinal vein occlusions are the second most common form of retinal vascular disease. Previously, laser treatment for branch retinal vein occlusion and intravitreal triamcinolone acetonide for central retinal vein occlusion were the standard of care. Recent studies have demonstrated that anti-vascular endothelial growth factor (anti-VEGF) agents have a superior safety and efficacy profile for the treatment of both branch and central retinal vein occlusions. The use of wide-field fluorescein angiography has also allowed better visualization of the retinal periphery...
2018: F1000Research
keyword
keyword
35594
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"